Sharmilan Thanendrarajan
Concepts (239)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 61 | 2025 | 3049 | 4.130 |
Why?
| | Antibodies, Bispecific | 6 | 2025 | 94 | 1.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 8 | 2024 | 606 | 0.900 |
Why?
| | Leukemia, Plasma Cell | 2 | 2020 | 33 | 0.840 |
Why?
| | Plasma Cells | 7 | 2025 | 239 | 0.770 |
Why?
| | Immunotherapy, Adoptive | 5 | 2024 | 167 | 0.690 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 5 | 2025 | 125 | 0.680 |
Why?
| | Bone Marrow | 10 | 2022 | 364 | 0.670 |
Why?
| | B-Cell Maturation Antigen | 7 | 2025 | 98 | 0.670 |
Why?
| | Neoplasms, Plasma Cell | 3 | 2024 | 37 | 0.620 |
Why?
| | Humans | 70 | 2025 | 52336 | 0.580 |
Why?
| | Chromosome Deletion | 2 | 2023 | 142 | 0.570 |
Why?
| | Gene Expression Profiling | 11 | 2025 | 1110 | 0.550 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 35 | 0.540 |
Why?
| | Diffusion Magnetic Resonance Imaging | 4 | 2025 | 133 | 0.540 |
Why?
| | Positron-Emission Tomography | 5 | 2025 | 303 | 0.540 |
Why?
| | Neoplasm, Residual | 7 | 2025 | 173 | 0.530 |
Why?
| | Prognosis | 17 | 2025 | 2094 | 0.510 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 224 | 0.510 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 468 | 0.500 |
Why?
| | Transplantation, Autologous | 9 | 2024 | 488 | 0.500 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2021 | 858 | 0.490 |
Why?
| | Aged | 25 | 2025 | 10109 | 0.470 |
Why?
| | Proteasome Inhibitors | 1 | 2016 | 105 | 0.470 |
Why?
| | Immunologic Factors | 1 | 2016 | 117 | 0.470 |
Why?
| | Immunotherapy | 1 | 2016 | 244 | 0.430 |
Why?
| | Translocation, Genetic | 5 | 2021 | 265 | 0.420 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 481 | 0.410 |
Why?
| | Mutation | 7 | 2022 | 1351 | 0.410 |
Why?
| | Neoplasm Proteins | 4 | 2020 | 334 | 0.390 |
Why?
| | Neutropenia | 2 | 2023 | 115 | 0.380 |
Why?
| | Stem Cell Transplantation | 4 | 2022 | 185 | 0.370 |
Why?
| | Survival Analysis | 8 | 2024 | 671 | 0.370 |
Why?
| | Cytokine-Induced Killer Cells | 1 | 2011 | 2 | 0.370 |
Why?
| | Neoplasms | 2 | 2012 | 1305 | 0.360 |
Why?
| | Lymphocytes | 1 | 2012 | 150 | 0.360 |
Why?
| | Evolution, Molecular | 2 | 2021 | 95 | 0.340 |
Why?
| | Cancer Vaccines | 1 | 2011 | 78 | 0.340 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 643 | 0.340 |
Why?
| | Middle Aged | 23 | 2025 | 13014 | 0.320 |
Why?
| | Aged, 80 and over | 10 | 2025 | 3391 | 0.310 |
Why?
| | Female | 29 | 2025 | 28105 | 0.310 |
Why?
| | Cytokines | 1 | 2012 | 625 | 0.300 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 255 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1031 | 0.280 |
Why?
| | Hematologic Neoplasms | 2 | 2022 | 106 | 0.280 |
Why?
| | Male | 27 | 2025 | 26696 | 0.270 |
Why?
| | Adult | 19 | 2025 | 14139 | 0.270 |
Why?
| | Combined Modality Therapy | 4 | 2024 | 636 | 0.260 |
Why?
| | Atrial Fibrillation | 2 | 2022 | 200 | 0.260 |
Why?
| | Disease Progression | 7 | 2025 | 870 | 0.240 |
Why?
| | Fluorodeoxyglucose F18 | 4 | 2021 | 188 | 0.230 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2020 | 81 | 0.230 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2025 | 63 | 0.230 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.220 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 77 | 0.210 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2023 | 96 | 0.200 |
Why?
| | Risk Factors | 9 | 2024 | 3872 | 0.190 |
Why?
| | Paraproteinemias | 1 | 2022 | 74 | 0.190 |
Why?
| | Immunoconjugates | 1 | 2022 | 37 | 0.190 |
Why?
| | Osteolysis | 1 | 2022 | 75 | 0.190 |
Why?
| | Drug Approval | 1 | 2022 | 46 | 0.190 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.190 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 61 | 0.190 |
Why?
| | Recurrence | 6 | 2024 | 672 | 0.180 |
Why?
| | Treatment Outcome | 7 | 2022 | 5407 | 0.180 |
Why?
| | Epigenomics | 1 | 2021 | 75 | 0.180 |
Why?
| | Patient Participation | 1 | 2022 | 69 | 0.180 |
Why?
| | T-Lymphocytes | 4 | 2024 | 340 | 0.180 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 74 | 0.170 |
Why?
| | Cell Cycle | 1 | 2021 | 240 | 0.170 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 487 | 0.170 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| | Bone Resorption | 1 | 2022 | 302 | 0.170 |
Why?
| | Bone Diseases | 1 | 2021 | 95 | 0.160 |
Why?
| | Retrospective Studies | 8 | 2025 | 6578 | 0.160 |
Why?
| | Chromosomal Instability | 1 | 2019 | 16 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 111 | 0.160 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.160 |
Why?
| | Disease-Free Survival | 5 | 2019 | 460 | 0.160 |
Why?
| | Antigens, CD | 1 | 2020 | 219 | 0.160 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 299 | 0.150 |
Why?
| | Spleen | 1 | 2019 | 173 | 0.150 |
Why?
| | Spinal Fractures | 1 | 2018 | 38 | 0.150 |
Why?
| | Phosphotransferases | 1 | 2018 | 17 | 0.150 |
Why?
| | Bacteremia | 1 | 2019 | 90 | 0.140 |
Why?
| | Brain Neoplasms | 2 | 2011 | 290 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 1222 | 0.140 |
Why?
| | Adipocytes | 1 | 2018 | 130 | 0.140 |
Why?
| | Gene Rearrangement | 1 | 2018 | 75 | 0.140 |
Why?
| | Hexokinase | 1 | 2017 | 16 | 0.140 |
Why?
| | Retinoblastoma Binding Proteins | 1 | 2017 | 11 | 0.140 |
Why?
| | Flow Cytometry | 1 | 2018 | 404 | 0.130 |
Why?
| | Calcification, Physiologic | 1 | 2017 | 42 | 0.130 |
Why?
| | Pelvis | 1 | 2017 | 69 | 0.130 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 407 | 0.130 |
Why?
| | Cell Proliferation | 4 | 2023 | 1029 | 0.130 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 106 | 0.130 |
Why?
| | Survival Rate | 4 | 2020 | 940 | 0.130 |
Why?
| | Immunoglobulin Light Chains | 1 | 2017 | 90 | 0.130 |
Why?
| | Clonal Evolution | 1 | 2016 | 58 | 0.130 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 181 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2017 | 140 | 0.120 |
Why?
| | Gene Expression | 1 | 2018 | 623 | 0.120 |
Why?
| | Transcriptome | 3 | 2025 | 367 | 0.110 |
Why?
| | Animals | 4 | 2024 | 13523 | 0.110 |
Why?
| | Cystatin M | 2 | 2024 | 19 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 1676 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2017 | 486 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2024 | 2268 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2011 | 58 | 0.090 |
Why?
| | Astrocytoma | 1 | 2011 | 19 | 0.090 |
Why?
| | Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| | Disease Models, Animal | 1 | 2016 | 1484 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2023 | 263 | 0.090 |
Why?
| | Glioma | 1 | 2011 | 78 | 0.090 |
Why?
| | Genomics | 2 | 2023 | 270 | 0.080 |
Why?
| | Alleles | 2 | 2021 | 277 | 0.080 |
Why?
| | Remission Induction | 2 | 2021 | 218 | 0.080 |
Why?
| | Tumor Burden | 2 | 2020 | 136 | 0.080 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 69 | 0.080 |
Why?
| | Histones | 2 | 2021 | 316 | 0.080 |
Why?
| | Vaccination | 1 | 2011 | 297 | 0.080 |
Why?
| | Transcription Factors | 2 | 2023 | 574 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 117 | 0.070 |
Why?
| | Radiopharmaceuticals | 2 | 2021 | 205 | 0.070 |
Why?
| | Models, Biological | 1 | 2011 | 743 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2022 | 674 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 484 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 150 | 0.060 |
Why?
| | Biopsy | 2 | 2018 | 604 | 0.060 |
Why?
| | ROC Curve | 1 | 2025 | 251 | 0.060 |
Why?
| | Arkansas | 2 | 2021 | 2028 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 36 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 116 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 79 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 132 | 0.050 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2024 | 57 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 152 | 0.050 |
Why?
| | Mice | 2 | 2024 | 5965 | 0.050 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| | Signal Transduction | 2 | 2021 | 1716 | 0.050 |
Why?
| | Patients | 1 | 2022 | 51 | 0.050 |
Why?
| | Geography | 1 | 2022 | 66 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2022 | 34 | 0.050 |
Why?
| | Patient Selection | 1 | 2023 | 259 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 98 | 0.050 |
Why?
| | Oncogenes | 1 | 2021 | 60 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 113 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 297 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 440 | 0.050 |
Why?
| | Syndecan-1 | 1 | 2021 | 73 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 234 | 0.050 |
Why?
| | RANK Ligand | 1 | 2022 | 187 | 0.040 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2021 | 128 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 77 | 0.040 |
Why?
| | Chromatin | 1 | 2021 | 141 | 0.040 |
Why?
| | Pyrimidines | 1 | 2022 | 199 | 0.040 |
Why?
| | Cyclin D2 | 1 | 2020 | 21 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 18 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 236 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 32 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 57 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 55 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 32 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 121 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 75 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 146 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 230 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 180 | 0.040 |
Why?
| | Osteoclasts | 1 | 2022 | 428 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 230 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1436 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 590 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2022 | 216 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 179 | 0.040 |
Why?
| | Computational Biology | 1 | 2020 | 211 | 0.040 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 30 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 54 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 247 | 0.040 |
Why?
| | Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 429 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 474 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 61 | 0.040 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 8 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 89 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 54 | 0.030 |
Why?
| | Retinoblastoma Protein | 1 | 2017 | 19 | 0.030 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 46 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2017 | 63 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 2017 | 88 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 124 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 155 | 0.030 |
Why?
| | Bone and Bones | 1 | 2021 | 494 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 591 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 94 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 230 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 52 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 328 | 0.030 |
Why?
| | Glycolysis | 1 | 2016 | 73 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 172 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 592 | 0.030 |
Why?
| | Genomic Instability | 1 | 2016 | 89 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2016 | 97 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 280 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 920 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 150 | 0.030 |
Why?
| | Melphalan | 1 | 2016 | 181 | 0.030 |
Why?
| | Heart | 1 | 2017 | 357 | 0.030 |
Why?
| | Kidney Diseases | 1 | 2017 | 220 | 0.030 |
Why?
| | Algorithms | 1 | 2018 | 668 | 0.030 |
Why?
| | Echocardiography | 1 | 2017 | 412 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2957 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 377 | 0.030 |
Why?
| | Myocardium | 1 | 2017 | 480 | 0.030 |
Why?
| | Disease Management | 1 | 2015 | 188 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 741 | 0.030 |
Why?
| | Risk Assessment | 1 | 2018 | 1323 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1377 | 0.030 |
Why?
| | Ifosfamide | 1 | 2011 | 9 | 0.020 |
Why?
| | Dacarbazine | 1 | 2011 | 11 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 1162 | 0.020 |
Why?
| | Carboplatin | 1 | 2011 | 57 | 0.020 |
Why?
| | Etoposide | 1 | 2011 | 72 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 196 | 0.020 |
Why?
| | Treatment Failure | 1 | 2011 | 122 | 0.020 |
Why?
| | United States | 1 | 2022 | 5182 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 372 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 1543 | 0.020 |
Why?
|
|
Thanendrarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|